CN110603044B - 通过抑制或调节t细胞受体信号转导治疗t细胞耗竭的方法 - Google Patents

通过抑制或调节t细胞受体信号转导治疗t细胞耗竭的方法 Download PDF

Info

Publication number
CN110603044B
CN110603044B CN201880029045.8A CN201880029045A CN110603044B CN 110603044 B CN110603044 B CN 110603044B CN 201880029045 A CN201880029045 A CN 201880029045A CN 110603044 B CN110603044 B CN 110603044B
Authority
CN
China
Prior art keywords
car
cells
cell
domain
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880029045.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN110603044A (zh
Inventor
瑞秋·琳恩
克里斯托·麦考尔
汤姆·J·万德莱斯
埃文·温伯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of CN110603044A publication Critical patent/CN110603044A/zh
Application granted granted Critical
Publication of CN110603044B publication Critical patent/CN110603044B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4258—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN201880029045.8A 2017-03-31 2018-03-30 通过抑制或调节t细胞受体信号转导治疗t细胞耗竭的方法 Active CN110603044B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762479930P 2017-03-31 2017-03-31
US62/479,930 2017-03-31
PCT/US2018/025459 WO2018183888A2 (en) 2017-03-31 2018-03-30 Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling

Publications (2)

Publication Number Publication Date
CN110603044A CN110603044A (zh) 2019-12-20
CN110603044B true CN110603044B (zh) 2024-11-05

Family

ID=63677091

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201880029045.8A Active CN110603044B (zh) 2017-03-31 2018-03-30 通过抑制或调节t细胞受体信号转导治疗t细胞耗竭的方法
CN202410272411.XA Pending CN118161496A (zh) 2017-03-31 2018-03-30 通过抑制或调节t细胞受体信号传导来治疗t细胞耗竭的方法
CN201880028993.XA Active CN110582280B (zh) 2017-03-31 2018-03-30 通过抑制或调节t细胞受体信号传导来治疗t细胞耗竭的方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202410272411.XA Pending CN118161496A (zh) 2017-03-31 2018-03-30 通过抑制或调节t细胞受体信号传导来治疗t细胞耗竭的方法
CN201880028993.XA Active CN110582280B (zh) 2017-03-31 2018-03-30 通过抑制或调节t细胞受体信号传导来治疗t细胞耗竭的方法

Country Status (7)

Country Link
US (3) US11938153B2 (enExample)
EP (2) EP3600323A4 (enExample)
JP (6) JP7249287B2 (enExample)
CN (3) CN110603044B (enExample)
AU (3) AU2018243664B2 (enExample)
CA (2) CA3057372A1 (enExample)
WO (2) WO2018183888A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021505604A (ja) * 2017-12-07 2021-02-18 ユリウス−マクシミリアン−ウニヴェルシテート・ヴュルツブルク ダサチニブ及び他のチロシンキナーゼ阻害剤を用いる遺伝子改変されたキメラ抗原受容体ｔ細胞の機能の制御及び調節
US20210393628A1 (en) * 2018-10-30 2021-12-23 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for modulating t cell exhaustion
MX2021005366A (es) 2018-11-08 2021-09-10 Juno Therapeutics Inc Metodos y combinaciones para el tratamiento y modulacion de celulas t.
EP3931216A4 (en) * 2019-03-01 2023-04-19 National University of Singapore MANIPULATED IMMUNE CELLS
CN110157680A (zh) * 2019-05-08 2019-08-23 浙江大学 提高嵌合抗原受体t细胞疗效和作用持久性的细胞培养方法
JP7505784B2 (ja) * 2019-08-01 2024-06-25 国立大学法人三重大学 Ｇｄ２結合性分子
CN115768879A (zh) 2020-04-28 2023-03-07 莱尔免疫制药公司 用于培养细胞的方法
AU2021292932A1 (en) * 2020-06-19 2023-01-05 Chugai Seiyaku Kabushiki Kaisha Anti-T cell antigen-binding molecule for use in combination with angiogenesis inhibitor
CN116322691A (zh) * 2020-09-24 2023-06-23 豪夫迈·罗氏有限公司 T细胞双特异性抗体相关不良反应的预防或减轻
WO2022094314A1 (en) * 2020-10-30 2022-05-05 The University Of North Carolina At Chapel Hill Dual targeting chimeric antigen receptors
WO2022210487A1 (ja) * 2021-03-29 2022-10-06 タカラバイオ株式会社 抗原に特異的な受容体を発現する免疫細胞の製造方法
EP4071248A1 (en) 2021-04-07 2022-10-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Means and methods for enhancing receptor-targeted gene transfer
EP4334443A1 (en) * 2021-05-07 2024-03-13 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH Method for constitutive malt1 protease activation
CN113533729B (zh) * 2021-06-15 2024-09-06 北京大学人民医院 一种鉴定aml患者骨髓中nk细胞耗竭的研究方法及其应用
EP4370541A1 (en) 2021-07-14 2024-05-22 2seventy bio, Inc. Engineered t cell receptors fused to binding domains from antibodies
CN115677861A (zh) * 2021-07-29 2023-02-03 上海科技大学 一种泛素偶联修饰的嵌合抗原受体及免疫细胞
WO2023077026A1 (en) 2021-10-28 2023-05-04 Lyell Immunopharma, Inc. Methods for culturing cells expressing ror1-binding protein
CA3234826A1 (en) 2021-10-28 2023-05-04 Lyell Immunopharma, Inc. Methods for culturing cells expressing c-jun
CN119546327A (zh) 2022-04-08 2025-02-28 再生元制药公司 多部分受体和信号传导复合物
KR20250036972A (ko) * 2022-06-13 2025-03-14 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 개선된 글리칸 의존성 키메라 항원 수용체 세포
GB202218144D0 (en) * 2022-12-02 2023-01-18 Univ Oxford Innovation Ltd Product
CN116121196B (zh) * 2022-12-23 2025-07-22 广州安捷生物医学技术有限公司 一种调控car-t细胞的方法与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106536563A (zh) * 2014-03-06 2017-03-22 Ucl商务股份有限公司 嵌合抗原受体

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057294A (en) 1995-01-16 2000-05-02 Northern Sydney Area Health Service Of Pacific Highway Peptide
US20050070478A1 (en) 1996-06-11 2005-03-31 Northern Sydney Area Health Services T cell antigen receptor peptides
US20050113564A1 (en) 2003-11-05 2005-05-26 St. Jude Children's Research Hospital Chimeric receptors with 4-1BB stimulatory signaling domain
GB0523954D0 (en) 2005-11-24 2006-01-04 Ucb Celltech Bioassays
US9334330B2 (en) 2006-10-10 2016-05-10 Universite De Nantes Use of monoclonal antibodies specific to the O-acetylated form of GD2 ganglioside for the treatment of certain cancers
US8173792B2 (en) * 2007-02-09 2012-05-08 The Board Of Trustees Of The Leland Stanford Junior University Method for regulating protein function in cells using synthetic small molecules
EP2664916B1 (en) 2007-04-02 2017-02-08 Acoustic Cytometry Systems, Inc. Method for manipulating a fluid medium within a flow cell using acoustic focusing
US9493740B2 (en) 2010-09-08 2016-11-15 Baylor College Of Medicine Immunotherapy of cancer using genetically engineered GD2-specific T cells
US9845362B2 (en) 2010-10-08 2017-12-19 The University Of North Carolina At Charlotte Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CN107188969B (zh) 2011-04-08 2021-08-27 美国卫生和人力服务部 抗-表皮生长因子受体变体iii嵌合抗原受体及其用于治疗癌症的用途
MX360823B (es) 2011-05-24 2018-11-16 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh Vacunas individualizadas para el cancer.
WO2013059593A1 (en) 2011-10-20 2013-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd22 chimeric antigen receptors
EP2785884B1 (en) * 2011-12-02 2020-06-24 Stillwater Mining Company Platinum group metal recovery
WO2013154760A1 (en) 2012-04-11 2013-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting b-cell maturation antigen
WO2014055771A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
LT2956175T (lt) 2013-02-15 2017-12-11 The Regents Of The University Of California Chimerinis antigeno receptorius ir jo panaudojimo būdai
SG11201505896YA (en) 2013-02-20 2015-09-29 Novartis Ag Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
US9446105B2 (en) 2013-03-15 2016-09-20 The Trustees Of The University Of Pennsylvania Chimeric antigen receptor specific for folate receptor β
US9790282B2 (en) 2013-03-25 2017-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
KR102238226B1 (ko) 2013-05-14 2021-04-09 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 가공된 키메라 항원 수용체 (ｃａｒ) ｔ-세포의 인간 적용
US9636340B2 (en) * 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
WO2015179801A1 (en) * 2014-05-23 2015-11-26 University Of Florida Research Foundation, Inc. Car based immunotherapy
WO2016011264A1 (en) * 2014-07-16 2016-01-21 Genentech, Inc. Methods of treating cancer using tigit inhibitors and anti-cancer agents
BR112017001242A2 (pt) 2014-07-21 2017-12-05 Novartis Ag tratamento de câncer usando um receptor antigênico quimérico a cd33
SG10201900455YA (en) * 2014-07-24 2019-02-27 Bluebird Bio Inc Bcma chimeric antigen receptors
MY189028A (en) 2014-08-19 2022-01-20 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
WO2016061368A1 (en) 2014-10-15 2016-04-21 The Children's Hospital Of Philadelphia Compositions and methods for treating b-lymphoid malignancies
GB201500319D0 (en) 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
WO2016134284A1 (en) * 2015-02-19 2016-08-25 University Of Florida Research Foundation, Inc. Chimeric antigen receptors and uses thereof
EP3270936A4 (en) 2015-03-17 2018-08-08 Chimera Bioengineering Inc. Smart car devices, de car polypeptides, side cars and uses thereof
GB201514328D0 (en) 2015-08-12 2015-09-23 Sigmoid Pharma Ltd Compositions
WO2017127755A1 (en) 2016-01-20 2017-07-27 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
AU2017244108B2 (en) * 2016-03-29 2021-03-18 University Of Southern California Chimeric antigen receptors targeting cancer
SI3443096T1 (sl) * 2016-04-15 2023-07-31 Novartis Ag Sestavki in postopki za selektivno izražanje himerni antigenskih receptorjev
JP7098615B2 (ja) * 2016-12-05 2022-07-11 フェイト セラピューティクス，インコーポレイテッド 養子免疫療法における免疫細胞調節のための組成物および方法
JP2021505604A (ja) 2017-12-07 2021-02-18 ユリウス−マクシミリアン−ウニヴェルシテート・ヴュルツブルク ダサチニブ及び他のチロシンキナーゼ阻害剤を用いる遺伝子改変されたキメラ抗原受容体ｔ細胞の機能の制御及び調節
US20210393628A1 (en) 2018-10-30 2021-12-23 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for modulating t cell exhaustion

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106536563A (zh) * 2014-03-06 2017-03-22 Ucl商务股份有限公司 嵌合抗原受体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A general chemical method to regulate protein stability in the mammalian central nervous system;Iwamoto M等;Chem Biol;第17卷(第9期);第981-988页 *
Design of chimeric antigen receptors with integrated controllable transient functions;Juillerat A等;Sci Rep;第6卷;18950:1-7 *
Juillerat A等.Design of chimeric antigen receptors with integrated controllable transient functions.Sci Rep.2016,第6卷18950:1-7. *

Also Published As

Publication number Publication date
CA3057505A1 (en) 2018-10-04
US20210032363A1 (en) 2021-02-04
CN110582280B (zh) 2024-03-19
CN110582280A (zh) 2019-12-17
AU2018243664B2 (en) 2024-02-01
AU2018243571B2 (en) 2024-03-07
WO2018183888A2 (en) 2018-10-04
JP7249287B2 (ja) 2023-03-30
EP3600323A1 (en) 2020-02-05
US20200101108A1 (en) 2020-04-02
US11938153B2 (en) 2024-03-26
CN118161496A (zh) 2024-06-11
CA3057372A1 (en) 2018-10-04
AU2018243664A1 (en) 2019-10-17
EP3600323A4 (en) 2020-11-11
JP2023055805A (ja) 2023-04-18
WO2018183888A3 (en) 2018-11-08
AU2018243571A1 (en) 2019-10-17
JP2024153812A (ja) 2024-10-29
WO2018183842A1 (en) 2018-10-04
JP2025026930A (ja) 2025-02-26
JP7278961B2 (ja) 2023-05-22
AU2024203919A1 (en) 2024-07-04
JP2023025187A (ja) 2023-02-21
EP3600357A2 (en) 2020-02-05
JP2020515259A (ja) 2020-05-28
CN110603044A (zh) 2019-12-20
EP3600357A4 (en) 2021-01-06
US20240293461A1 (en) 2024-09-05
JP2020515581A (ja) 2020-05-28
JP7674328B2 (ja) 2025-05-09

Similar Documents

Publication Publication Date Title
CN110603044B (zh) 通过抑制或调节t细胞受体信号转导治疗t细胞耗竭的方法
JP7757343B2 (ja) 改変ｔ細胞に関する方法および組成物
US10800840B2 (en) Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer
JP7109789B2 (ja) 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法
US10696749B2 (en) Enhancing activity of CAR T cells by co-introducing a bispecific antibody
KR102697827B1 (ko) 키메릭 항원 수용체를 발현하는 변형된 단핵세포/대식세포 및 그의 용도
ES2963718T3 (es) Capacidad presentadora de antígenos de células CAR-T potenciada mediante introducción conjunta de moléculas co-estimuladoras
CN107995913B (zh) 使用融合蛋白对tcr重编程的组合物和方法
JP2019536452A (ja) 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
KR20230088333A (ko) 입양 세포 요법을 위한 표적화된 공동자극을 제공하는 수용체
US20210269501A1 (en) Compositions and methods of nkg2d chimeric antigen receptor t cells for controlling triple-negative breast cancer
EP3340998B1 (en) Methods and compositions for cells expressing a chimeric intracellular signaling molecule
HK40040144A (en) Enhancing activity of car t cells by co-introducing a bispecific antibody
HK40004389A (en) Compositions and methods for tcr reprogramming using fusion proteins
HK1257442B (en) Methods and compositions for cells expressing a chimeric intracellular signaling molecule

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant